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Available online 8 June 2014One of the most interesting ﬁndings in the ﬁeld of neurodegeneration in recent years is tfche discovery of a ge-
netic mutation in the C9orf72 gene, the most common mutation found to be causative of sporadic and familial
frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and concomitant FTD-ALS
(DeJesus-Hernandez et al., 2011b; Renton et al., 2011). While clinical and molecular data, such as the identiﬁca-
tion of TDP-43 being a common pathological protein (Neumann et al., 2006) have hinted at such a link for years,
the identiﬁcation of what was formally known as “the chromosome 9 FTLD-ALS gene” has provided a foundation
for better understanding of the relationship between the two. Indeed, it is now recognized that ALS and FTLD-TDP
represent a disease spectrum. In this review, we will discuss the current genetic and pathological features of the
FTLD-ALS spectrum.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Frontotemporal lobar degeneration (FTLD) is a group of complex
disorders resulting from the progressive deterioration of the frontal
and anterior temporal lobes of the brain. It is the second most common
form of presenile dementia (after Alzheimer's disease) with a preva-
lence estimated between 10 and 30 per 100,000 in individuals between-Brown).
. This is an open access article underthe ages of 45 and 65 years (Sieben et al., 2012). While the grouping of
these disorders may give the impression that they have much in com-
mon, in fact FTLD is clinically and genetically heterogeneous, and also
differs greatly in pathology.
The subcategories of the disease are deﬁned by their dominant clinical
symptom in patients; behavioural variant frontotempotal dementia
(bvFTD) that accounting for two-thirds of patients, and two language var-
iants classiﬁed on their effects onﬂuency (progressivenon-ﬂuent aphasia,
PNFA) or semantic difﬁculties in communicative speech and understand-
ing the semantic content of language (semantic dementia, SD).the CC BY license (http://creativecommons.org/licenses/by/3.0/).
85J. Bennion Callister, S.M. Pickering-Brown / Experimental Neurology 262 (2014) 84–90Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenera-
tive disease in which the loss of motor neurons from the brain and spi-
nal cord is usually fatal due to respiratory paralysis within 1–5 years of
symptom onset (Mitchell and Borasio, 2007). While 1–2 people per
100,000 are currently affected by the disease worldwide, the reality is
that 1 in 800 individuals are expected to develop ALS in their lifetime
due to the short course of disease progression, making it themost com-
mon adult-onset motor neuron disorder (Redler and Dokholyan, 2012).
Prior to the emergence of evidence to the contrary, ALS was widely
reported as having a sparing of cognitive ability, sensation, and auto-
nomic nervous function, as a result of the restriction of cell death to
the motor neurons. It has not yet been conclusively proven whether
the primary site of such dysfunction is the upper motor neurons
(UMN) that originate in the motor cortex and are not directly responsi-
ble for stimulating the target skeletal muscle, or the lower motor
neurons (LMN) that continue the signal to the muscle following glu-
tamate release from the UMN. The interconnectedness of these sys-
tems, which are both required for target muscle movement, makes it
difﬁcult to decipher the speciﬁcs, leading to much debate (Redler
and Dokholyan, 2012).
It has now been established that FTLD and ALS can co-occur in the
same individual, and more recently the focus has switched away from
a simple co-incidence hypothesis to a popular recognition of a spectrum
of disease, supported by the clustering of neurodegenerative diseases in
relatives of patients with ALS (Al-Chalabi et al., 2012). Up to half of ALS
patients show some degree of functional loss in frontal lobe tests, and in
15% of cases this is sufﬁcient to warrant an ofﬁcial diagnosis of FTLD
(Ringholz et al., 2005). At the other end of the spectrum, around 40%
of FTLD cases havemeasurablemotor dysfunctionwith up to 15% ﬁtting
with the ALS classiﬁcation (Burrell et al., 2011).
With the emergence of this relationship between FTLD and ALS, it
has become more important to use care when referring to any given
point on the spectrum, and so nomenclature has naturally developed
alongside it. The current terminology refers to patients who do not
meet the criteria for FTLD, but do have behavioural or cognitive deﬁcits
as ALS with cognitive or behavioural impairment (ALS Ci/ALS Bi). Pa-
tients with FTLD who show somemotor neuron involvement on a clin-
ical or electronmyograph level without actually developing ALS are
referred to as FTLD-MND or FTLD-MND-like. Those who fall at the mid-
way point are referred to as ALS-FTLD or FTLD-ALS; the order is usually
dependent on the clinical symptoms that appeared ﬁrst. Now that the
spectrum is widely accepted within the FTLD and ALS research commu-
nity, it makes sense that novel ﬁndings in either ﬁeld will be investigat-
ed in the other, and a clearer picture will start to emerge.
‘Pure’ FTLD
MAPT
FTLD is a proteinopathy that can be sub-categorized pathologically
based on the major constituent of the abnormal, ubiquitinated protein
inclusions that characteristically reside in the cytoplasm and nucleus
of neuronal and glial cells.
The ﬁrst reported genetic linkage in FTLD families with autosomal
dominant disinhibition, dementia, parkinsonism, and amyotrophy was
to chromosome 17q21 (Wilhelmsen et al., 1994), and was subsequent-
ly, following a consensus conference, named FTDP-17 (Foster et al.,
1997; Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al.,
1998b). The knowledge that most FTDP-17 cases presented with inclu-
sions that stained positive for the microtubule-associated protein Tau
(albeit with great variability) led to analysis of theMAPT gene on chro-
mosome 17q21. These investigations identiﬁed the ﬁrst novel missense
and slice-site mutations in MAPT associated with FTLD (Clark et al.,
1998; Hutton et al., 1998; Spillantini et al., 1998a).
Following on from those initial mutations, a total of 44 different
MAPT mutations have been reported (http://www.molgen.ua.ac.be/).These changes result in either an exonic missense mutation or interfer-
ence with alternative splicing, disrupting the ratio of tau isoform ex-
pression (Hutton et al., 1998).
The normal function of Tau is to promote the assembly of tubulin
microtubules via interaction with its microtubule domain, modulating
stability (Lee et al., 1989). It is a phosphoprotein mainly expressed in
neurons, with phosphorylation status important for microtubule bind-
ing (Biernat et al., 1993; Gustke et al., 1992; Miyasaka et al., 1993).
There are six tau isoforms that are expressed in adult brain tissue, pro-
duced by alternative splicing of exons 2, 3, and 10 (Goedert et al.,
1989). Half the naturally occurring isoforms of tau contain three imper-
fect repeats of ~32 amino acids in the microtubule domain at the c-
terminus (3R) and the other contain four (4R), controlled by alternative
splicing of exon 10. The 4R form of tau has the strongest association
with microtubules of the two and is often referred to as being more
‘sticky’ (Gustke et al., 1994). Mutations that disturb alternative splicing
regulation lead to an increase in the 4R form over 3R, and (along with
missense mutations in exon 10) are associated with a tauopathy com-
posed of four-repeat tau.
Families with missense or splice site mutations affecting exon 10
have neuronal and glial inclusions while families with mutations out-
side of exon 10 have neuronal inclusions only, comprised of all six iso-
forms (Grover et al., 1999). Disruption of a normal equimolar 3R to 4R
ratio of tau isoforms may be sufﬁcient to drive aggregation, as it has
been shown that even spiking small amounts of 3R tau into a 4R aggre-
gation model inhibits assembly (Hutton, 2001).Progranulin
Following the discovery ofMAPTmutations in FTDP-17 families, ev-
idence started to amass that it may not be the sole gene responsible for
the disease in patients with linkage to this region. Those showing clini-
cal symptoms of FTD underwent extensive mutation analysis and some
were found to havemutation-freeMAPT. Further investigation of neuro-
nal inclusions did not show Tau-positive staining, but did stain for ubiq-
uitin (Rosso and van Swieten, 2002). In 2006, mutational analysis of
nearby genes showed that indeed there was a second gene, granulin
(GRN), within the region of chromosome17q21, 1.7 Mb centromeric to
MAPT, which had mutations (Baker et al., 2006; Cruts et al., 2006).
This GRN gene encodes a cysteine-rich secreted glycoprotein
(Songsrirote et al., 2010) implicated in tissue repair (He and Bateman,
2003), glucose sensing (Kim et al., 2011), and cancer (He and
Bateman, 1999; He et al., 2002; Swamydas et al., 2011). The gene prod-
uct of GRN, progranulin (PGRN) can be proteolytically cleaved by en-
zymes such as elastase into small peptides, known as granulins (Zhu
et al., 2002). Granulins arise from a 12 cysteine granulin motif that
form (pre-cleavage) six disulphide bridges (Hrabal et al., 1996)
resulting in a parallel stack of beta-hairpins (Hrabal et al., 1996;
Tolkatchev et al., 2008). Full-length progranulin also contains a signal
peptide, which aids in transportation to the Golgi and through to the
plasmamembrane for secretion. During progress through the endoplas-
mic reticulum, carbohydrates are added at several aspargine-linked gly-
cosylation sequences and it is ﬁnally targeted to the plasma membrane
where the signal peptide is cleaved and the mature glycoprotein
secreted.
Until late 2011 mutations in the GRN gene were the most frequent
known cause of familial FTLD, at up to 20% (Baker et al., 2006; Cruts
et al., 2006; Mackenzie et al., 2010; Rademakers and Hutton, 2007).
Pathological GRN mutations found to date cause disease as a function
of haploinsufﬁciency, with mutations producing a premature termina-
tion of the coding sequence being largely to blame. The resultant mes-
senger RNA (mRNA) undergoes nonsense-mediated decay and the
truncated protein is not translated. In addition, a splicingmutation lead-
ing to retention of an intron and nuclear degradation of GRNmRNA can
also be a cause (Cruts et al., 2006).
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PGRN (see database at http://www.molgen.ua.ac.be/ADMutations/),
though to date only one of these has been conﬁrmed as truly pathogen-
ic. This change of an alanine to an aspartic acid (A9D) within the signal
peptide at the N-terminus of PGRN results in a loss of PGRN secretion
(Mukherjee et al., 2006).
Screening of ALS and ALS-FTD patients shows that GRN mutations
are not a common cause of ALS phenotypes, placing PGRN at the FTLD
end of the spectrum (Schymick et al., 2007). There has been a ﬁrst re-
port of a patient with an A9D mutation with clinical and pathological
symptoms of ALS (Cannon et al., 2013). It should be noted that this is
currently conﬁned to a single case, and as such it is possible that the pa-
tient had concomitant ALS. More research in this area is required.
Upon autopsy, individualswith FTLDwithGRNmutations exhibit ce-
rebral atrophy (most severe in the frontal lobes), frequently with a
shrunken caudate nucleus and a loss of substantia nigra pigmentation
(Mackenzie et al., 2006b). The majority of cases have also suffered a
loss of pyramidal neurons. While FTLD-TDPmolecular pathology is het-
erogeneous, the ﬁndings in cases with PGRN mutation show a highly
consistent pattern corresponding to FTLD-TDP Type A (see below),
that being numerous short dystrophic neurites (DN) and crescentic or
oval neuronal cytoplasmic inclusions (NCI), concentrated primarily in
neocortical layer 2. In addition, this subtype is also has amoderate num-
ber of lentiformneuronal intranuclear inclusions (NII) (Mackenzie et al.,
2011).The middle ground
TDP-43
TAR DNA-binding protein (TDP-43) is a 414 amino acid nuclear pro-
tein, encoded by TARDBP, a chromosome 1 gene. Before its role in FTLD
and ALSwas uncovered, TARDBPwas cloned from a screen for TAR DNA
of HIV type 1 binding, and found to be a heterogeneous ribonucleopro-
tein (hnRNP) with two RNA recognition motifs (Kumar-Singh, 2011).
Functioning as a transcriptional regulator involved in RNA splicing and
stability. TDP-43 has since been identiﬁed as a component of NCI in all
FTLD-TDP43 subtypes, as well as in sporadic ALS (sALS) (Neumann
et al., 2006). While missense and nonsense mutations in TARDBP do
occur on the FTLD-ALS spectrum, they do so with a frequency of less
than 1% in FTLD and around 1% in ALS (Van Langenhove et al., 2012).
In 2006, the majority of cases with tau-negative inclusions that
stained positive for ubiquitin in FTLD (known as FTLD-U) were found
to contain TDP-43 protein, as did the majority of sALS and some fALS
cases (Neumann et al., 2006). This information, combined with work
by the same group categorising subtypes of FTLD-U by differential label-
ing of pathology (Sampathu et al., 2006) and a second group studying
clinicopathological correlations (Mackenzie et al., 2006a) a clear pattern
started to emerge, followed by combined classiﬁcation system for what
are now known as the FTLD-TDP subtypes (Mackenzie et al., 2011).
Around half of FTLD-TDP type A are familial cases, and as already
mentioned earlier, are most often associated with progranulin muta-
tions (which are always FTLD-TDP43 type A). More recently they have
been found also to contain the repeat expansion mutation in the
C9orf72 gene (described below). The inclusions found in this subtype
include neuronal cytoplasmic inclusions (NCIs) neuronal intranuclear
inclusions (NIIs) and dystrophic neurites (DNs), usually in layer II of
the cerebral cortex. Clinically, the presentation is usually bvFTD or
PNFA (and occasionally with SD).
Type B FTLD-TDP43 is associated with FTD-ALS and bvFTD. Patholo-
gy also includes NCIs, though fewer and they can be throughout the en-
tire cortical thickness, while NIIs and DNs are rare. Males are more
frequently affected in this category, and as might be expected from
the ALS link, it is the group with the shortest life expectancy at just
over ﬁve years on average. Early studies genetically linked many casesof this subtype to chromosome 9p, now known to be caused by a
hexanucleotide expansion mutation (GGGGCC) in the gene C9orf72.
Type C FTLD-TDP43, like type A, is predominantly in layer II and is
most frequently associatedwith SD (andoccasionally bvFTD). It features
longDN in superﬁcial cortical layers, and no current linkage to any gene.
Type D FTLD-TDP43 have few NCI, and instead many NII and DN
throughout all layers. This subtype is associated with valosin-containing
protein (VCP) mutations, and is very rare at less than 1% of familial
FTLD. Clinical presentation for type D is familial Inclusion bodymyopathy
with Paget Disease of Bone and frontotemporal dementia (IBMPFD).
TDP-43 is predominantly found in the nucleus, but shuttles between
there and the cytoplasm, where it is present only at low levels. When
this translocation to the nucleus is inhibited in cells in culture, TDP-43
is accumulated and sequestered as cytoplasmic aggregates, echoing
pathological ﬁndings in brain and spinal cord sections from FTLD-U
and sALS cases showing clearance of nuclear TDP43 in favour of similar
cytoplasmic aggregates (Winton et al., 2008).
The neuropathology of sALS is inmost cases characterized by TDP-43
cytoplasmic accumulation in neurons and glia of the primarymotor cor-
tex, brainstem motor nuclei, spinal cord, and associated white matter
tracts(Mackenzie et al., 2007). Such cases are termed ALS-TDP, and
this pathology does not overlap with SOD1 mutations, which are
discussed below. However TDP-43 was identiﬁed from a genome wide
RNAi screen for SOD1 regulators, an observation conﬁrmed bybiochem-
ical analysis that provides an interesting link between SOD1 fALS and
ALS-TDP (Somalinga et al., 2012).
FUS
Fused in sarcoma (FUS, also known as translocated in liposarcoma,
TLS) is a 526 amino acid protein with several conserved domains; a
transcriptional activation domain, multiple nucleic acid binding domains
(three arginine-glycine-glycine boxes, an RNA recognition motif, a zinc-
ﬁnger) and a nuclear localization signal (NLS). It was identiﬁed as a fusion
oncogene causing humanmyxoid liposarcomas, where aberrant chromo-
somal translocation results in the N-terminus being fused to a transcrip-
tion factor (Dormann and Haass, 2013). When in the nucleus, FUS is
thought to be involved in regulation of transcription and pre-mRNA splic-
ing. Cytoplasmic FUS in neurons appears to have a role in mRNA trans-
port, where it can potentially facilitate local protein synthesis at synapse
(Colombrita et al., 2012).
Mutations in the FUS gene were identiﬁed as a cause of fALS in 2009,
representing around 4% of fALS in the studies with 14 mutations in 26
unrelated families (Kwiatkowski et al., 2009; Vance et al., 2009). The
FUS protein was found to be deposited in cytoplasmic inclusions in
these patients (Kwiatkowski et al., 2009). Most mutations were mis-
sense, autosomal dominant and affected exon 15, which encodes the
c-terminus of the protein. This clustering of mutations around exon 15
disrupts binding of FUS to Transportin, a nuclear import receptor that
shuttles proteins with a non-canonical NLS (such as that of FUS) from
the cytoplasm to the nucleus (Lee et al., 2006). This disruption by mis-
sense mutation in turn leads to an accumulation of mutant FUS in the
cytoplasm (see (Dormann and Haass, 2013) for a full review). FUS pa-
thology is often associatedwith a reduction in nuclear FUS staining con-
sistent with the idea that a nuclear importation defect is responsible
(Dormann and Haass, 2011). Interestingly, in cultured human cells a
fraction of TDP-43 is shown to be complexedwith FUS, and this interac-
tion is enhanced by TDP-43 mutant expression(Kim et al., 2010).
De novo mutations of FUS also account for a portion of sporadic ALS
cases. A splice-sitemutation in FUS intron 13 leads to C-terminal trunca-
tion of the protein (IVS13-2A N G) (DeJesus-Hernandez et al., 2010),
and a point mutation in exon ﬁfteen leads to missense mutation
R521C(Chio et al., 2011), a mutation that also occurs in fALS.
Though no patients from the above studies had features of FTLD,
studies by Neumann et al. (Neumann et al., 2009) found FUS co-local-
ized with all the ubiquitin-immunoreactive (ub-ir) inclusions in their
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additional inclusions in glial cells that were not ub-ir. This pathology
was observed in the absence of FUSmutation and this subtype is now
known as FTLD-FUS.
VCP
Valosin-containing protein (VCP, also known as p97) is a conserved,
multifunctional protein essential for growth in mice and other model
organisms (Muller et al., 2007). Highly abundant, it comprises around
1% of total cellular protein and is a member of the class II AAA (ATPases
associated with diverse cellular activities) family. VCP forms homo-
hexamers, and N-terminal domain (N-domain) binding of various co-
factors plays a role in the multi-functionality of the protein, enabling it
to target speciﬁc substrates for degradation via the ubiquitin–protea-
some system. Known roles include ER and golgi reassembly, nuclear en-
velope regeneration, proteolysis, spindle disassembly, chromosome
condensation, DNA damage response, DNA replication, suppression of
protein aggregation, autophagy, ER-associated protein degradation
and sex determination (Yamanaka et al., 2012).
More recent research has enhanced our understanding of VCP's
mode of action with relevance to neurodegenerative disease. VCP pro-
tein contains two ATPase domains (known as D1 and D2), and its deﬁ-
ciency results in mitochondrial uncoupling and a signiﬁcant reduction
of cellular ATP production (Bartolome et al., 2013). This decrease in
ATP levels lowers the energy capacity of the cell, rendering them more
vulnerable to high energy-demanding processes such as ischemia. Re-
search has also shown that stress granule clearance, a process important
for clearance of pathogenic ribonucleoprotein is impaired by depletion
or pathogenic mutation of VCP (Buchan et al., 2013).
Ubiquitinated inclusions found in muscle, bone and brain are a fea-
ture of inclusion body myopathy with Paget's disease of bone and
frontotemporal dementia (IBMPFD), which can lead to disablingmuscle
weakness (Inclusion body myopathy-IBM), osteolytic bone lesions
(Paget's disease of bone-PDB), and neurodegeneration (FTD).VCPmuta-
tions are an underlying cause of IBMPFD, and 6 missense mutations
were found in a total of 13 families with the disease originally (Watts
et al., 2004), with the number of identiﬁed mutations now around 20
from 50 unrelated families (http://www.molgen.ua.ac.be/ftdmutations).
Myopathy is themost common clinical symptom of individuals with
IBMPFD occurring in 80–90% of patients and manifesting as adult-onset
(~44 years) with proximal and distal muscle weakness (Guinto et al.,
2007). Patients show a progressive muscle weakness typically starting
in pelvic and shoulder region and spreading to the heart and respiratory
system. Though this may be confused with ALS due to the age of onset,
muscle weakness, and even evidence of neuropathic changes usually
consistent with motor neuron degeneration, electromyography shows
myopathic changes in affected individuals, and histological analysis of
affected muscles by biopsy shows myonuclear and sarcoplasmic inclu-
sion bodies reactive with ubiquitin and TDP-43 (Nalbandian et al.,
2011). The dementia aspect of the disease presents later (~54 years
old), and is only present in around a third of patients.
In terms of neurodegeneration, VCPwas considered an FTLD-related
gene, due to its characteristic language and/or behavioural dysfunction
and FTLD-TDP D type pathology. However, mutations have also been
found to be responsible for autosomal dominant fALS in an Italian family
in which SOD1, TARDBP and FUS mutations were previously excluded
(Johnson et al., 2010). This ﬁnding demonstrates that some individuals
with a VCP mutation do have motor neuron disease as part of the phe-
notype along with myopathy, further muddying the water in diagnosis
of disease. Further analysis has shown that VCPmutations were present
in ~1–2% of a large cohort of fALS cases from unrelated families, and
other research has supported this interpretation (DeJesus-Hernandez
et al., 2011a; Shaw, 2010).
The most common mutation of VCP in FTLD or ALS is R155H, which
like other VCP mutant gene products results in a normal hexametricstructure (Weihl et al., 2006). However, mutations here induce con-
formational alterations in the N-domain, resulting from impaired
communication between the D1 and N domains (Fernandez-Saiz and
Buchberger, 2010). It has been suggested that this imbalanced co-factor
binding is an important determinant of IBMPFD pathology, possibly by
trapping functioning VCP in unproductive co-factor complexes. The
sheer number of co-factor interactions with VCP may underlie the highly
variable nature of pathology and clinical presentation.
C9orf72
The C9orf72 gene encodes a protein of unknown function, recently
identiﬁed in silico as a potential DENN-type GEF (Levine et al., 2013;
Zhang et al., 2012). DENN (differentially expressed in normal and neo-
plastic cells) domain proteins act as speciﬁc regulators of the Rab
GTPase family, functioning enzymatically as guanine nucleotide ex-
change factors (GEFs). A likely function of the gene product based on
structural similarity, is to regulate membrane trafﬁc in conjunction
with Rab-GTPase switches, though this has yet to be validated experi-
mentally (Levine et al., 2013).
In late 2011, a repeat mutation in the ﬁrst intron of C9orf72 was
found to be the most common genetic cause of cause of fALS and FTD
(DeJesus-Hernandez et al., 2011b; Renton et al., 2011). This mutation
is thought to be responsible for around 40% of fALS and 21% of FTD., seg-
regating perfectlywith disease. Themutation is a hexanucleotide repeat
with the sequence GGGGCC, ranging from zero-30 copies in unaffected
individuals, to an excess of four thousand in mutation carriers, and re-
duces the expression of at least one RNA species (DeJesus-Hernandez
et al., 2011b; Gijselinck et al., 2012; Renton et al., 2011), and forms nu-
clear RNA foci (DeJesus-Hernandez et al., 2011b).
This C9orf72 mutation is also the most frequent cause of apparently
sporadic ALS and FTD found to date, accounting for 5–7% of cases in
white Americans, Europeans and Australians (Majounie et al., 2012).
Majounie et al. postulate that these cases are actually cryptically related
familial ones, occurring for various reasons such as unfamiliarity with
the pedigree, previous generations dying at a young age before onset
of neurological symptoms and incomplete penetrance of the mutation.
Though themechanism behind it is unclear, the ﬁnding that penetrance
of this mutation seems to be complete only at a late stage of life argues
against the notion that late-onset neurodegeneration has non-genetic
etiologies.
This mutation makes C9orf72 cases of FTLD/ALS the most recent
addition to the DNA-repeat expansion associated disease. More than
40 other neurological, neurodegenerative or neuromuscular disorders
are linked to repeat instability,which unlike staticmutations, have a dy-
namic repeat process with products continuing to mutate across gener-
ations and in different tissue types.
The appearance of C9orf72mutations is frequently histologically cat-
egorized as a type B pathology, with inclusion bodies in neurons and in
glial cells (GCI) that are TDP-43 positive. Other expansion carriers, how-
ever, have a type A pathology with DN and NCI in the outer layers of the
cerebral cortex (Liu et al., 2013; Snowden et al., 2012).
Although the hexanucleotide repeat is found in the non-coding
region of the C9orf72 gene, an interesting phenomenon known as
repeat-associated non-ATG dependent translation (RAN translation) al-
lows expression of mutant proteins made of dipeptide repeats (DPRs)
from the expansion (Ash et al., 2013; Mori et al., 2013). RAN translation
occurs in the absence of the ATG codon and from both strands. Usually
required to initiate this form of translation is long hairpin forming re-
peats as ﬁrst described in relation to spinocerebellar ataxia type 8 and
myotonic dystrophy type 1 (Zu et al., 2011). Antibodies generated
against C9orf72 repeat DPRs from the forward strand of the mutation
detect highmolecular weight material in brain homogenate fromwest-
ern blotting, and detects neuronal inclusions through the central ner-
vous system of C9 FTLD/ALS cases (Ash et al., 2013). The alternative
frame translation products produced by the forward strand are
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is no stop codon present in the (GGGGCC)n repeat, once RAN translation
is initiated it may produce extremely large proteins, repeat-size depen-
dent. DPRs from the alternate strand are also foundwithin the cytoplas-
mic and intra nuclear inclusions in cases with the expansion (Mann
et al., 2013).
Though aberrant proteinsmay be the cause of some of the patholog-
ical effects of the C9orf72 expansion mutation, there is not currently
sufﬁcient evidence to state that they are the sole cause. Other research
points towards a ‘toxic RNA’ hypothesis (Haeusler et al., 2014; Lee
et al., 2013) and current thinking in the ﬁeld often refers to the possibil-
ity of amultiple toxic effect of both themutant protein and RNA. Studies
have shown that the RNA of the C9orf72 expansion has a propensity for
forming highly stable guanine quadruplexes (G-quadruplexes), and
secondary structures formed from short tracts of G-rich sequence
associating together (Fratta et al., 2012). RNA foci composed of the
hexanucleotide repeat have been found in brain tissue, but their role
in pathogenicity is as yet unclear (van Blitterswijk et al., 2012).
P62/sequestosome-1
p62, encoded for by the SQSTM1 gene, is another multifunctional
protein at the intersection of ALS and FTLD pathology. Unlike the
other genes mentioned in this review, its inclusion in the spectrum
was found through a candidate gene approach following the observa-
tion of involvement of the p62 in ALS (Fecto et al., 2011). p62 is a
stress-inducible intracellular protein, and is involved in the regulation
of cell survival and death via regulation of cell signal transduction. As
is common for such pathways, a mechanism of feedback occurs in that
p62 can both suppress autophagy via activation of the mammalian tar-
get of rapamycin complex 1 (TORC1) and can itself be regulated by au-
tophagy in terms of protein levels (Komatsu et al., 2012). An N-terminal
Phox and Bam1p (PB1) domain is responsible for self- and hetero olig-
omerization of p62, and targeting of the protein to the autophagosome
is also dependent on this region of the protein (Itakura and Mizushima,
2011). Here it interactswith LC3, is incorporated into the autophagosome
and is degraded by autophagy.
Inclusions positive for p62 can be found in C9orf72 expansionmuta-
tion patients, both with and without TDP-43 pathology. These latter in-
clusions stain for p62 and ubiquitin only, and are frequently reported as
presentedwith compact globular or star-shapedNCIs and spherical NIIs,
abundant in the granular layer (Liu et al., 2013). These NCI and GCI
found in the frontal neocortex, cerebellum and hippocampus are rare
in non- C9orf72 cases, and so are regarded as the pathological hallmark
of C9orf72 mutation carriers.
At its c-terminal, p62 has a ubiquitin-associated (UBA) domain, and
is a marker for ubiquitinated cargos targeted for proteosomal degrada-
tion. Originally, mutations in the section of SQSTM1 encoding the UBA
domain were reported to cause Paget's disease of bone (PDB) (Goode
and Layﬁeld, 2010), highlighting a relationship to IBMPFD. Following
the candidate gene approach identiﬁcation of SQSTM1mutation, it has
been further reported in ALS and in FTLD (Chen et al., 2014; Hirano
et al., 2013; Le Ber et al., 2013; Rubino et al., 2012; Shimizu et al.,
2013; Teyssou et al., 2013).
Ubiquilin 2
The UBQLN2 gene encodes ubiquilin-2 (UBQLN2), a member of the
ubiquilin (UBQLN) family that regulates degradation of ubiquitinated
proteins. Mutations in this gene have been found in very rare cases of
dominantly inherited chromosome-X-linked ALS (X-ALS) and ALS
with FTLD (Deng et al., 2011). Pathological analysis of these individuals
revealed axonal loss in the cortico-spinal tract, loss of anterior horn
cells, and astrocytosis in the anterior horn of the spinal cord. UBQLN2
positive inclusions were detected in spinal motor neurons of mutation
carriers, along with immunoreactivity with p62, ubiquitin, and FUSbut not SOD1. UBQLN2 and ubiquitin also co-localize in inclusions
of the hippocampus in brain tissue from dementia-linked UBQLN2
mutation.
Interestingly, UBQLN2 pathology could also be found in brain and
spinal cord tissue of ALS or FTLD patients without mutated a UBQLN2
gene (Deng et al., 2011). This UBQLN (ubiquilin family rather than
UBQLN2 speciﬁcally) pathology in ALS and FTLD-TDP cases with a
C9ORF72 expansion was conﬁrmed by others and is highly distinct
(Brettschneider et al., 2012). In the hippocampus of FTLD-TDP and ALS
with C9ORF72 expansion, dystrophic neurites that showed focal
swellings and dot-like stipples and irregular, aggregate-like formations
were extensive in the hippocampal molecular layer and in the CA1–CA4
region. The clearly distinguishable neuropathological disease signature
observed by the authors in ALS and FTLD-TDP cases with and with-
out C9ORF72 expansion, suggests a pathophysiological link between
C9ORF72 and UBQLN pathology.‘Pure’ ALS
SOD1
Superoxide dismutase 1 (SOD1)was theﬁrst gene identiﬁed to cause
familial ALS (FALS) in 1993, with the original authors citing 11 different
missensemutations in 13 families (Rosen et al., 1993). Since then, more
than 170 mutations have been recorded in positions that span the
whole of the resulting protein (http://alsod.iop.kcl.ac.uk/Als/index.
aspx).12% of fALS, while absent in ALS-FTLD (Chio et al., 2012), have
not been found in FTLD patients to date. Individuals with SOD1 muta-
tions have ubiquitin-positive neuronal inclusions, but they are negative
for TDP-43 immunoreactivity (Mackenzie et al., 2007).
SOD1 is a 153 amino acid protein predominantly expressed in the
cytosol of most cells that are exposed to oxygen. It forms a homodimer
following zinc and copper ion complexing that acts as a dismutase;
removing superoxide radicals by metabolizing them to molecular oxy-
gen and hydrogen peroxide, thus providing a defense against oxygen
toxicity. Mice lacking SOD1 suffer extensive oxidative damage in the
cytoplasm of liver cells from as early as 3 months, leading to persistent
and widespread damage and hepatocarcinogenesis in later life (Elchuri
et al., 2005).
Themajority of ALS SOD1mutations are of themissense variety,with
a few C-terminal truncations due to nonsense or deletion mutations.
The mutations are mostly dominant with the notable exception of
D90A, recessive in Scandinavian populations for reasons as yet not
fully understood (Robberecht and Philips, 2013). In terms of stability,
somemutations (for example, C6S and D90A) are as stable as the native
SOD1 molecule, and others (for example A4V and G127del) are highly
unstable. Most mutations have been found to cause a reduction in
dismutase activity, while some (for example G37R, A89V and D90A)
are essentially normal or only slightly reduced in activity (Andersen
and Al-Chalabi, 2011).
The debate over loss or gain of function that has revolved around
these mutations has now been quashed with the use of mouse models.
Transgenic mice over-expressing mutant human SOD1 have increased
SOD1 activity and a loss of motor neurons that models human ALS,
andmice carrying amutant SOD1 transgene (tgSOD1G85R) on a normal
mouse background compared with the same transgene in a SOD1 null
background showed no change in survival. (Bruijn et al., 1998). While
this ruled out the role of loss of function of SOD1, it has been suggested
that while not causative, theremay be amodifying effect of loss of SOD1
function in ALS (Saccon et al., 2013).
The most common underlying mutation in SOD1 varies with geo-
graphical location. In the U.S.A., it is A4V, with around 50% of SOD1-ALS
patients carrying thismutation. In Japan it is H46R (in the catalytic copper
ion binding site), affecting 40% of SOD1-ALS patients with a much longer
disease course than the average (around 15 years).
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SOD1, if not a change in stability or function? The ﬁnding that the SOD1
protein was actually present in aggregates in fALS postmortem patients
and also transgenic mice suggested that, similar to other neurodegener-
ative diseases, the aggregating pathology of ALS could be linked to mu-
tations in this gene (Bruijn et al., 1998).Wild type SOD1 lacking both its
metal ions gives rise to soluble oligomers under aerobic physiological
conditions, formed by intermolecular disulphide covalent bonds and
non-covalent interactions between beta-strands (Banci et al., 2007).
The overarching theme then, borne out by further experiments on
known fALS mutations, is that metal-free SOD1 is a cause of ALS, and
that some mutants associated with the disease may be more prone to
oligomerize in vivo due to alterations in metal binding or the stability
of that binding (Banci et al., 2008).
Concluding remarks
We have gained much in our understanding of FTLD and ALS in re-
cent years. From the progress that has been made in our understanding
of the molecular genetics of FTLD and ALS over this time, it is clear that
at least a subsection of these disorders form part of a disease spectrum
with the same gene implicated in both. However, it is clear that there
are subtypes which appear, generally, to be exclusive. The reports of
ALS in cases with MAPT and PGRN mutations have to be conﬁrmed as
does dementia in ALS resulting from SOD1 mutations. Nevertheless,
one observation that has come from the realization of a disease spec-
trum is that it is highly likely that any drugs that are developed for
one end will likely be efﬁcacious for the other.
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